Angiogenesis imaging with vascular-constrained particles: The why and how

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue SUPPL. 1, 2010, Pages

  Lanza, Gregory M ^a   Caruthers, Shelton D ^a   Winter, Patrick M ^a   Hughes, Michael S ^a   Schmieder, Anne H ^a   Hu, Grace ^a   Wickline, Samuel A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Fluorine 19; Microbubble; Molecular imaging; MRI; Nanoparticle; Perfluorocarbon; Ultrasound

Indexed keywords

AGM 1883; ARGINYLGLYCYLASPARTIC ACID; ATORVASTATIN; BEVACIZUMAB; DOXORUBICIN; FLUORINE; FLUOROCARBON; FLUORODEOXYGLUCOSE F 18; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; MATRIGEL; MELITTIN; NANOPARTICLE; PACLITAXEL; POLYLACTIC ACID; RAPAMYCIN; SORAFENIB; SUNITINIB; SUPERPARAMAGNETIC IRON OXIDE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VITRONECTIN RECEPTOR;

AMINO ACID SEQUENCE; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC GENE THERAPY; ANTIANGIOGENIC THERAPY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CANCER RISK; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTRAST ENHANCEMENT; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE MARKER; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; EARLY DIAGNOSIS; GENE EXPRESSION PROFILING; GENE TARGETING; HEART MUSCLE ISCHEMIA; HUMAN; IMMUNOCHEMISTRY; INTERNALIZATION; MICROBUBBLE; MOLECULAR IMAGING; NANOENCAPSULATION; NEOVASCULARIZATION (PATHOLOGY); NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PANCREAS TUMOR; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROTEIN MOTIF; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; BLOOD VESSELS; HUMANS; MOLECULAR IMAGING; NANOPARTICLES; NEOVASCULARIZATION, PATHOLOGIC;

EID: 77956266423     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1502-5     Document Type: Review

References (107)

1. RH Adams K Alitalo 2007 Molecular regulation of angiogenesis and lymphangiogenesis Nat Rev Mol Cell Biol 8 464 478 17522591
2. J Folkman 1971 Tumor angiogenesis: therapeutic implications N Engl J Med 285 1182 1186 4938153
3. N Ferrara KJ Hillan W Novotny 2005 Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy Biochem Biophys Res Commun 333 328 335 15961063
4. MH Cohen J Gootenberg P Keegan R Pazdur 2007 FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer Oncologist 12 713 718 17602060
5. MH Cohen J Gootenberg P Keegan R Pazdur 2007 FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer Oncologist 12 356 361 17405901
6. L Lang 2008 FDA approves sorafenib for patients with inoperable liver cancer Gastroenterology 134 379
7. EP Rock V Goodman JX Jiang K Mahjoob SL Verbois D Morse, et al. 2007 Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma Oncologist 12 107 113 17227905
8. FA Eskens J Verweij 2006 The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review Eur J Cancer 42 3127 3139 17098419
9. HM Verheul HM Pinedo 2007 Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition Nat Rev Cancer 7 475 485 17522716
10. LJ Wilmes MG Pallavicini LM Fleming J Gibbs D Wang KL Li, et al. 2007 AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging Magn Reson Imaging 25 319 327 17371720
11. G Liu HS Rugo G Wilding TM McShane JL Evelhoch C Ng, et al. 2005 Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study J Clin Oncol 23 5464 5473 16027440
12. MO Leach KM Brindle JL Evelhoch JR Griffiths MR Horsman A Jackson, et al. 2005 The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations Br J Cancer 92 1599 1610 15870830
13. N Hylton 2006 Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker J Clin Oncol 24 3293 3298 16829653
14. G Korpanty JG Carbon PA Grayburn JB Fleming RA Brekken 2007 Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature Clin Cancer Res 13 323 330 17200371
15. G Korpanty PA Grayburn RV Shohet RA Brekken 2005 Targeting vascular endothelium with avidin microbubbles Ultrasound Med Biol 31 1279 1283 16176794
16. G Korpanty S Chen RV Shohet J Ding B Yang PA Frenkel, et al. 2005 Targeting of VEGF-mediated angiogenesis to rat myocardium using ultrasonic destruction of microbubbles Gene Ther 12 1305 1312 15829992
17. S Pochon I Tardy P Bussat T Bettinger J Brochot M von Wronski, et al. 2010 BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis Invest Radiol 45 89 95 20027118
18. M De Nichilo G Burns 1993 Granulocyte-macrophage and macrophage colony-stimulating factors differentially regulate alpha v integrin expression on cultured human macrophages Proc Natl Acad Sci USA 90 2517 2521 7681600
19. O Helluin C Chan G Vilaire S Mousa WF DeGrado JS Bennett 2000 The activation state of alphavbeta 3 regulates platelet and lymphocyte adhesion to intact and thrombin-cleaved osteopontin J Biol Chem 275 18337 18343 10751402
20. H Itoh P Nelson L Mureebe A Horowitz K Kent 1997 The role of integrins in saphenous vein vascular smooth muscle cell migration J Vasc Surg 25 1061 1069 9201167
21. F Carreiras Y Denoux C Staedel M Lehmann F Sichel P Gauduchon 1996 Expression and localization of alpha v integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma Gynecol Oncol 62 260 267 8751559
22. T Kageshita CV Hamby S Hirai T Kimura T Ono S Ferrone 2000 Differential clinical significance of alpha(v)beta(3) expression in primary lesions of acral lentiginous melanoma and of other melanoma histotypes Int J Cancer 89 153 159 10754493
23. R Weissleder A Bogdanov Jr CH Tung HJ Weinmann 2001 Size optimization of synthetic graft copolymers for in vivo angiogenesis imaging Bioconjug Chem 12 213 219 11312682
24. H Leong-Poi J Christiansen AL Klibanov S Kaul JR Lindner 2003 Noninvasive assessment of angiogenesis by ultrasound and microbubbles targeted to alpha(v)-integrins Circulation 107 455 460 12551871
25. DB Ellegala H Leong-Poi JE Carpenter AL Klibanov S Kaul ME Shaffrey, et al. 2003 Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3 Circulation 108 336 341 12835208
26. JR Lindner J Song J Christiansen AL Klibanov F Xu K Ley 2001 Ultrasound assessment of inflammation and renal tissue injury with microbubbles targeted to P-selectin Circulation 104 2107 2112 11673354
27. BA Kaufmann JM Sanders C Davis A Xie P Aldred IJ Sarembock, et al. 2007 Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1 Circulation 116 276 284 17592078
28. RF Mattrey 1994 The potential role of perfluorochemicals (PFCs) in diagnostic imaging Artif Cells Blood Substit Immobil Biotechnol 22 295 313 8087248
29. R Mattrey F Scheible B Gosink G Leopold D Long C Higgins 1982 Perfluoroctylbromide: a liver/spleen-specific and tumor-imaging ultrasound contrast material Radiology 145 759 762 7146409
30. GM Lanza KD Wallace MJ Scott WP Cacheris DR Abendschein DH Christy, et al. 1996 A novel site-targeted ultrasonic contrast agent with broad biomedical application Circulation 94 3334 3340 8989148
31. GM Lanza RL Trousil KD Wallace JH Rose CS Hall MJ Scott, et al. 1998 In vitro characterization of a novel, tissue-targeted ultrasonic contrast system with acoustic microscopy J Acoust Soc Am 104 3665 3672 9857523
32. MS Hughes JE McCarthy JN Marsh JM Arbeit RG Neumann RW Fuhrhop, et al. 2007 Properties of an entropy-based signal receiver with an application to ultrasonic molecular imaging J Acoust Soc Am 121 3542 3557 17552706
33. MS Hughes JN Marsh JM Arbeit RG Neumann RW Fuhrhop KD Wallace, et al. 2009 Application of Renyi entropy for ultrasonic molecular imaging J Acoust Soc Am 125 3141 3145 19425656
34. M Hughes J Marsh C Hall J Allen P Brown E Lacy, et al. 2004 In vivo ultrasonic detection of angiogenesis with site-targeted nanoparticle contrast agents using measure-theoretic signal receivers Ultrason Symp 2 1106 1109
35. R Bekeredjian S Chen W Pan PA Grayburn RV Shohet 2004 Effects of ultrasound-targeted microbubble destruction on cardiac gene expression Ultrasound Med Biol 30 539 543 15121256
36. R Bekeredjian S Chen PA Frenkel PA Grayburn RV Shohet 2003 Ultrasound-targeted microbubble destruction can repeatedly direct highly specific plasmid expression to the heart Circulation 108 1022 1026 12912823
37. S Chen JH Ding R Bekeredjian BZ Yang RV Shohet SA Johnston, et al. 2006 Efficient gene delivery to pancreatic islets with ultrasonic microbubble destruction technology Proc Natl Acad Sci USA 103 8469 8474 16709667
38. R Chai S Chen J Ding PA Grayburn 2009 Efficient, glucose responsive and islet-specific transgene expression by a modified rat insulin promoter Gene Ther 16 1202 1209 19727136
39. S Chen J Ding C Yu B Yang DR Wood PA Grayburn 2007 Reversal of streptozotocin-induced diabetes in rats by gene therapy with betacellulin and pancreatic duodenal homeobox-1 Gene Ther 14 1102 1110 17460716
40. H Leong-Poi MA Kuliszewski M Lekas M Sibbald K Teichert-Kuliszewska AL Klibanov, et al. 2007 Therapeutic arteriogenesis by ultrasound-mediated VEGF165 plasmid gene delivery to chronically ischemic skeletal muscle Circ Res 101 295 303 17585071
41. JC Chappell J Song CW Burke AL Klibanov RJ Price 2008 Targeted delivery of nanopartides bearing fibroblast growth factor-2 by ultrasonic microbubble destruction for therapeutic arteriogenesis Small 4 1769 1777 18720443
42. K Hynynen N McDannold NA Sheikov FA Jolesz N Vykhodtseva 2005 Local and reversible blood-brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications Neuroimage 24 12 20 15588592
43. GM Lanza CH Lorenz SE Fischer MJ Scott WP Cacheris RJ Kaufmann, et al. 1998 Enhanced detection of thrombi with a novel fibrin-targeted magnetic resonance imaging agent Acad Radiol 5 Suppl 1 S173 S176 9561074
44. DA Sipkins DA Cheresh MR Kazemi LM Nevin MD Bednarski KC Li 1998 Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging Nat Med 4 623 626 9585240
45. A Schmieder P Winter S Caruthers T Harris T Williams J Allen, et al. 2005 MR molecular imaging of melanoma angiogenesis with ανβ3-targeted paramagnetic nanoparticles Magn Reson Med 53 621 627 15723405
46. WJ Mulder GJ Strijkers JW Habets EJ Bleeker DW van der Schaft G Storm, et al. 2005 MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle FASEB J 19 2008 2010 16204353
47. WJ Mulder DW van der Schaft PA Hautvast GJ Strijkers GA Koning G Storm, et al. 2007 Early in vivo assessment of angiostatic therapy efficacy by molecular MRI FASEB J 21 378 383 17202248
48. MM Pike CN Stoops CP Langford NS Akella LB Nabors GY Gillespie 2009 High-resolution longitudinal assessment of flow and permeability in mouse glioma vasculature: sequential small molecule and SPIO dynamic contrast agent MRI Magn Reson Med 61 615 625 19235262
49. AJ Nijdam TR Nicholson III JP Shapiro BR Smith JT Heverhagen P Schmalbrock, et al. 2009 Nanoparticulate iron oxide contrast agents for untargeted and targeted cardiovascular magnetic resonance imaging Curr Nanosci 5 88 102
50. F Hyodo GVR Chandramouli S Matsumoto KI Matsumoto JB Mitchell MC Krishna, et al. 2009 Estimation of tumor microvessel density by MRI using a blood pool contrast agent Int J Oncol 35 797 804 19724915
51. G Gambarota W Leenders C Maass P Wesseling B van der Kogel O van Tellingen, et al. 2008 Characterisation of tumour vasculature in mouse brain by USPIO contrast-enhanced MRI Br J Cancer 98 1784 1789 18506183
52. M Beaumont B Lemasson R Farion C Segebarth C Rémy EL Barbier 2009 Characterization of tumor angiogenesis in rat brain using iron-based vessel size index MRI in combination with gadolinium-based dynamic contrast-enhanced MRI J Cereb Blood Flow Metab 29 1714 1726 19584891
53. JA Frank BR Miller AS Arbab HA Zywicke EK Jordan BK Lewis, et al. 2003 Clinically applicable labeling of mammalian and stem cells by combining superparamagnetic iron oxides and transfection agents Radiology 228 480 487 12819345
54. SA Anderson J Glod AS Arbab M Noel P Ashari HA Fine, et al. 2005 Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model Blood 105 420 425 15331444
55. KA Kelly JR Allport A Tsourkas VR Shinde-Patil L Josephson R Weissleder 2005 Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle Circ Res 96 327 336 15653572
56. M Stuber WD Gilson M Schär DA Kedziorek LV Hofmann S Shah, et al. 2007 Positive contrast visualization of iron oxide-labeled stem cells using inversion-recovery with ON-resonant water suppression (IRON) Magn Reson Med 58 1072 1077 17969120
57. A Senpan S Caruthers I Rhee N Mauro D Pan G Hu, et al. 2009 Conquering the dark side: colloidal iron oxide nanoparticles ACS Nano 3 12 3917 3926 19908850
58. P Bachert 1998 Pharmacokinetics using fluorine NMR in vivo Prog Nucl Magn Reson Spectrosc 33 1 56
59. X Yu SK Song MJ Scott RJ Fuhrhop GM Lanza CS Hall, et al. 2000 Molecular characterization of thrombus using bimodal 1H/19F MR imaging with a novel fibrin-targeted nanoparticulate contrast agent Proc Int Soc Magn Reson Med 8 465
60. AM Morawski PM Winter X Yu RW Fuhrhop MJ Scott F Hockett, et al. 2004 Quantitative "magnetic resonance immunohistochemistry" with ligand-targeted (19)F nanoparticles Magn Reson Med 52 1255 1262 15562481
61. SD Caruthers AM Neubauer FD Hockett R Lamerichs PM Winter MJ Scott, et al. 2006 In vitro demonstration using (19)F magnetic resonance to augment molecular imaging with paramagnetic perfluorocarbon nanoparticles at 1.5 Tesla Invest Radiol 41 305 312 16481914
62. EA Waters J Chen JS Allen H Zhang GM Lanza SA Wickline 2008 Detection and quantification of angiogenesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine MRI/MRS J Cardiovasc Magn Reson 10 43 18817557
63. EA Waters J Chen X Yang H Zhang R Neumann A Santeford, et al. 2008 Detection of targeted perfluorocarbon nanoparticle binding using 19F diffusion weighted MR spectroscopy Magn Reson Med 60 1232 1236 18956417
64. Rahmer J, Keupp J, Caruthers S, Lips O, Williams T, Wickline S, et al. 19F/1H simultaneous 3D radial imaging of atherosclerotic rabbits using self-navigated respiratory motion compensation. Proc Int Soc Magn Reson Med 2009;4611.
65. Rahmer J, Keupp J, Caruthers S, Lips O, Williams T, Wickline S, et al. Dual resolution simultaneous 19F/1H in vivo imaging of targeted nanoparticles. Proc Int Soc Magn Reson Med 2009;611.
66. Keupp J, Caruthers S, Rahmer J, Williams T, Wickline S, Lanza G, et al. Fluorine-19 MR molecular imaging of angiogenesis on Vx-2 tumors in rabbits using ανβ3-targeted nanoparticles. Proc Int Soc Magn Reson Med 2009;223.
67. G Lanza X Yu P Winter D Abendschein K Karukstis M Scott, et al. 2002 Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis Circulation 106 2842 2847 12451012
68. N Soman G Lanza J Heuser P Schlesinger S Wickline 2008 Synthesis and characterization of stable fluorocarbon nanostructures as drug delivery vehicles for cytolytic peptides Nano Lett 8 1131 1136 18302330
69. KC Crowder MS Hughes JN Marsh AM Barbieri RW Fuhrhop GM Lanza, et al. 2005 Sonic activation of molecularly-targeted nanoparticles accelerates transmembrane lipid delivery to cancer cells through contact-mediated mechanisms: implications for enhanced local drug delivery Ultrasound Med Biol 31 1693 1700 16344131
70. T Cyrus H Zhang JS Allen TA Williams G Hu SD Caruthers, et al. 2008 Intramural delivery of rapamycin with alphavbeta3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury Arterioscler Thromb Vasc Biol 28 820 826 18292395
71. P Winter A Neubauer S Caruthers T Harris J Robertson T Williams, et al. 2006 Endothelial alpha(ν)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis Arterioscler Thromb Vasc Biol 26 2103 2109 16825592
72. AH Schmieder SD Caruthers H Zhang TA Williams JD Robertson SA Wickline, et al. 2008 Three-dimensional MR mapping of angiogenesis with {alpha}5{beta}1({alpha}{nu}{beta}3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model FASEB J 22 4179 4189 18697838
73. P Winter S Caruthers H Zhang T Williams S Wickline G Lanza 2008 Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis JACC Cardiovasc Imaging 1 624 634 19356492
74. PM Winter AH Schmieder SD Caruthers JL Keene H Zhang SA Wickline, et al. 2008 Minute dosages of alpha(nu)beta3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits FASEB J 22 2758 2767 18362202
75. N Soman S Baldwin G Hu J Marsh G Lanza J Heuser, et al. 2009 Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth J Clin Invest 119 2830 2842 19726870
76. J Marsh A Senpan G Hu M Scott P Gaffney S Wickline, et al. 2007 Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis Nanomedicine 2 533 543 17716136
77. S Liu J Widom CW Kemp CM Crews J Clardy 1998 Structure of human methionine aminopeptidase-2 complexed with fumagillin Science 282 1324 1327 9812898
78. N Sin L Meng MQ Wang JJ Wen WG Bornmann CM Crews 1997 The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2 Proc Natl Acad Sci USA 94 6099 6103 9177176
79. G Bergers K Javaherian KM Lo J Folkman D Hanahan 1999 Effects of angiogenesis inhibitors on multistage carcinogenesis in mice Science 284 808 812 10221914
80. V Castronovo D Belotti 1996 TNP-470 (AGM-1470): mechanisms of action and early clinical development Eur J Cancer 32A 2520 2527 9059342
81. H Konno T Tanaka T Kanai K Maruyama S Nakamura S Baba 1996 Efficacy of an angiogenesis inhibitor, TNP-470, in xenotransplanted human colorectal cancer with high metastatic potential Cancer 77 1736 1740 8608571
82. S Shusterman SA Grupp R Barr D Carpentieri H Zhao JM Maris 2001 The angiogenesis inhibitor TNP-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease Clin Cancer Res 7 977 984 11309349
83. P Bhargava JL Marshall N Rizvi W Dahut J Yoe M Figuera, et al. 1999 A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer Clin Cancer Res 5 1989 1995 10473076
84. AP Kudelka CF Verschraegen E Loyer 1998 Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470 N Engl J Med 338 991 992 9527612
85. AP Kudelka T Levy CF Verschraegen CL Edwards S Piamsomboon W Termrungruanglert, et al. 1997 A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix Clin Cancer Res 3 1501 1505 9815836
86. CJ Logothetis KK Wu LD Finn D Daliani W Figg H Ghaddar, et al. 2001 Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer Clin Cancer Res 7 1198 1203 11350884
87. R Offodile T Walton M Lee A Stiles M Nguyen 1999 Regression of metastatic breast cancer in a patient treated with the anti-angiogenic drug TNP-470 Tumori 85 51 53 10228498
88. AW Griffioen SC Tromp HF Hillen 1998 Angiogenesis modulates the tumour immune response Int J Exp Pathol 79 363 368 10319018
89. AW Griffioen IA Relou HI Gallardo Torres CA Damen S Martinotti JC De Graaf, et al. 1998 The angiogenic factor bFGF impairs leukocyte adhesion and rolling under flow conditions Angiogenesis 2 235 243 14517463
90. AW Griffioen CA Damen KH Mayo AF Barendsz-Janson S Martinotti GH Blijham, et al. 1999 Angiogenesis inhibitors overcome tumor induced endothelial cell anergy Int J Cancer 80 315 319 9935216
91. AW Griffioen CA Damen S Martinotti GH Blijham G Groenewegen 1996 Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors Cancer Res 56 1111 1117 8640769
92. AW Griffioen CA Damen GH Blijham G Groenewegen 1996 Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium Blood 88 667 673 8695814
93. S Kim M Harris J Varner 2000 Regulation of integrin alpha vbeta 3-mediated endothelial cell migration and angiogenesis by integrin alpha5beta1 and protein kinase A J Biol Chem 275 33920 33928 10944524
94. N Boudreau J Varner 2004 The homeobox transcription factor Hox D3 promotes integrin alpha5beta1 expression and function during angiogenesis J Biol Chem 279 4862 4868 14610084
95. PR Moreno KR Purushothaman V Fuster D Echeverri H Truszczynska SK Sharma, et al. 2004 Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability Circulation 110 2032 2038 15451780
96. PR Moreno KR Purushothaman M Sirol AP Levy V Fuster 2006 Neovascularization in human atherosclerosis Circulation 113 2245 2252 16684874
97. R Virmani FD Kolodgie AP Burke AV Finn HK Gold TN Tulenko, et al. 2005 Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage Arterioscler Thromb Vasc Biol 25 2054 2061 16037567
98. T Björnheden M Levin M Evaldsson O Wiklund 1999 Evidence of hypoxic areas within the arterial wall in vivo Arterioscler Thromb Vasc Biol 19 870 876 10195911
99. JJ Boyle B Wilson R Bicknell S Harrower PL Weissberg TP Fan 2000 Expression of angiogenic factor thymidine phosphorylase and angiogenesis in human atherosclerosis J Pathol 192 234 242 11004701
100. JJ Khatri C Johnson R Magid SM Lessner KM Laude SI Dikalov, et al. 2004 Vascular oxidant stress enhances progression and angiogenesis of experimental atheroma Circulation 109 520 525 14744973
101. OJ de Boer AC van der Wal P Teeling AE Becker 1999 Leucocyte recruitment in rupture prone regions of lipid-rich plaques: a prominent role for neovascularization? Cardiovasc Res 41 443 449 10341843
102. F Kolodgi J Narula C Yuan A Finn H Gold R Virmani 2007 Eliminating plaque angiogenesis: reply J Am Coll Cardiol 50 1521
103. R Khurana M Simons JF Martin IC Zachary 2005 Role of angiogenesis in cardiovascular disease: a critical appraisal Circulation 112 1813 1824 16172288
104. RK Jain AV Finn FD Kolodgie HK Gold R Virmani 2007 Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization Nat Clin Pract Cardiovasc Med 4 491 502 17712362
105. PM Winter AM Morawski SD Caruthers RW Fuhrhop H Zhang TA Williams, et al. 2003 Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles Circulation 108 2270 2274 14557370
106. GK Sukhova JK Williams P Libby 2002 Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol Arterioscler Thromb Vasc Biol 22 1452 1458 12231565
107. M Koutouzis A Nomikos S Nikolidakis V Tzavara V Andrikopoulos N Nikolaou, et al. 2007 Statin treated patients have reduced intraplaque angiogenesis in carotid endarterectomy specimens Atherosclerosis 192 457 463 17335827